Recent studies suggested that short-term inhibition of both BRAF and MEK in combination with anti-PD-1/L1 antibodies could enhance tumor immune infiltration, and improve tumor control in a CD8 T cells-dependent manner. The gene discussed is MAP2K7; the disease is neoplasm.